Prevention Of Bacterial Endocarditis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for prevention of bacterial endocarditis. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
3
Active US patents
68/100
Avg vulnerability
—
Annual revenue covered

Originators in Prevention Of Bacterial Endocarditis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating prevention of bacterial endocarditis. Each bar = one year. Y-axis scaled to peak year (2 patents).

1
26
2
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cleocin T
CLINDAMYCIN PHOSPHATE
 Pfizer 3 68 — 2026-12-02

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9789057 Cleocin T method of use 80 2026-12-02
11129896 Cleocin T method of use 70 2036-09-22
12303563 Cleocin T formulation 55 2036-09-22

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12303563 Cleocin T formulation 55 2036-09-22
11129896 Cleocin T method of use 70 2036-09-22
9789057 Cleocin T method of use 80 2026-12-02

Related